C. Difficile

University of Minnesota
Completed Trials
Recurrent C. difficile Infection: Bacterial Engraftment after Intestinal Microbial Transplant
  • In this trial, researchers monitored stool samples of patients successfully treated with Intestinal Microbiota Transplant capsules for recurrent C. difficile infections over a period of a year. All patients recovered clinically and none had exposure to antibiotics after transplant during the trial period.
  • The majority of patients' microbiota resembled that of the donor throughout the entire period. However, in a quarter of patients the microbiota became entirely different from the donor at one year. In a minority of patients we did not see much in the way of donor microbiota at all.
  • Read the full cited research publication here.
University of Minnesota
Trials underway
Diet Optimization for C. difficile patients after FMT

This clinical trial is investigating how a Microbiota Enhancing and Nourishing Diet (MEND) can impact gut microbial health in patients who have received a Fecal Microbiota Transplant for recurrent C. difficile infections. More information about the trial is available here.

Veterans Administration Medical System
Trials underway
C. difficile Infections Multi-Center Trial

This phase 2 clinical trial is investigating the efficacy of Fecal Microbiota Transplant in treating recurrent C. difficile infections. More information on the clinical trial is available here.

University of Wisconsin, Madison
Trials underway
C. difficile Infection in Solid Organ Transplant Recipients

A phase 2 double blind, double placebo-controlled clinical trial studying the impact of Fecal Microbiota Transplant in treating recurrent C. difficile Infections in solid organ transplant recipients. Trial details are available here.

University of Minnesota
Indiana University
Brown University
Harvard University
Trials underway
C. difficile Infections Clinical Treatment Registry

Clinicians and providers in this collaborative trial are actively treating patients with recurrent C. difficile infections through Intestinal Microbiota Transplants and maintaining a single registry evaluating clinical results.